Saxagliptin and metformin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with metformin

Current Medical Research and Opinion

Volumn 26, Issue 10, 2010, Pages 2355-2363

  Stenlöf, Kaj ^a   Raz, Itamar ^b   Neutel, Joel ^c   Ravichandran, Shoba ^d   Berglind, Niklas ^d   Chen, Roland ^d  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c Orange County Research Center   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

Author keywords

Combination therapy; DPP 4 inhibitor; Metformin XR; Saxagliptin; Type 2 diabetes mellitus

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; METFORMIN; PLACEBO; SAXAGLIPTIN;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BLOOD TOXICITY; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC PATIENT; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; LIVER TOXICITY; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 2 CLINICAL TRIAL; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; THROMBOCYTOPENIA;

ADAMANTANE; ADMINISTRATION, ORAL; ADULT; AGED; BLOOD GLUCOSE; CIRCADIAN RHYTHM; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PLACEBOS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 77956747341     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.511090     Document Type: Article

References (19)

1. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:541-559
2. Onglyza [package insert]. Princeton NJ: Bristol-Myers Squibb Company/ Wilmington DE: AstraZeneca Pharmaceuticals LP; July 2009
3. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132:2131-2157
4. Flatt PR, Bailey CJ, Green BD. Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes. Front Biosci 2008;13:3648-3660
5. Drucker DJ. The biology of incretin hormones. Cell Metab 2006;3:153-165
6. DeFronzo RA, Hissa M, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes on metformin alone. Diabetes Care 2009;32:1649-1655
7. Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab 2008;10:376-386
8. Rosenstock J, Aguilar-Salinas C, Klein E, et al. Effect of saxagliptin mono-therapy in treatment-na?̈ve patients with type 2 diabetes. Curr Med Res Opin 2009;25:2401-2411
9. Chacra AR, Tan GH, Apanovitch A, et al. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract 2009;63:1395-1406
10. Hollander P, Li J, Allen E, et al. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab 2009;94:4810-4819
11. Jadzinsky M, Pfü tzner A, Paz-Pacheco E, et al. Saxagliptin given in combination with metformin as initial therapy improves glycemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009;11:611-622
12. Hermansen K, Mortensen LS. Bodyweight changes associated with antihy-perglycaemic agents in type 2 diabetes mellitus. Drug Saf 2007;30:1127-1142
13. Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006;295:1681-1687
14. Marfella R, Barbieri M, Grella R, et al. Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations. J Diabetes Complications 2010;24:79-83
15. Brazg R, Xu L, Dalla Man C, et al. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. Diabetes Obes Metab 2007; 9:186-193
16. Ahrén B, Landin-Olsson M, Jansson PA, et al. Inhibition of dipeptidyl pepti-dase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004;89:2078-2084
17. Inzucchi SE, McGuire DK. New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond. Circulation 2008;117:574-584
18. McGarraugh G, Bergenstal R. Detection of hypoglycemia with continuous interstitial and traditional blood glucose monitoring using the FreeStyle Navigator Continuous Glucose Monitoring System. Diabetes Technol Ther 2009;11:145-150
19. DeFronzo R, Hissa MN, Garber AJ, et al. Once daily saxagliptin added to metformin provides sustained glycemic control and is well tolerated over 102 weeks in patients with T2D [abstract]. Diabetes 2009;58 (Suppl. 1):A147